Université catholique de Louvain, Brussels, Belgium.
Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E761-9. doi: 10.1152/ajpendo.00421.2009. Epub 2010 Jan 5.
Like insulin, leucine stimulates the mammalian target of rapamycin (mTOR)/p70 ribosomal S6 kinase (p70(S6K)) axis in various organs. Insulin proceeds via the canonical association of phosphatidylinositol 3-kinase (PI3K), phosphoinositide-dependent protein kinase-1 (PDK1), and protein kinase B (PKB/Akt). The signaling involved in leucine effect, although known to implicate a PI3K mechanism independent of PKB/Akt, is more poorly understood. In this study, we investigated whether PDK1 could also participate in the events leading to mTOR/p70(S6K) activation in response to leucine in the heart. In wild-type hearts, both leucine and insulin increased p70(S6K) activity whereas, in contrast to insulin, leucine was unable to activate PKB/Akt. The changes in p70(S6K) activity induced by insulin and leucine correlated with changes in phosphorylation of Thr(389), the mTOR phosphorylation site on p70(S6K), and of Ser(2448) on mTOR, both related to mTOR activity. Leucine also triggered phosphorylation of the proline-rich Akt/PKB substrate of 40 kDa (PRAS40), a new pivotal mTOR regulator. In PDK1 knockout hearts, leucine, similarly to insulin, failed to induce the phosphorylation of mTOR and p70(S6K), leading to the absence of p70(S6K) activation. The loss of leucine effect in absence of PDK1 correlated with the lack of PRAS40 phosphorylation. Moreover, the introduction in PDK1 of the L155E mutation, which is known to preserve the insulin-induced and PKB/Akt-dependent phosphorylation of mTOR/p70(S6K), suppressed all leucine effects, including phosphorylation of mTOR, PRAS40, and p70(S6K). We conclude that the leucine-induced stimulation of the cardiac PRAS40/mTOR/p70(S6K) pathway requires PDK1 in a way that differs from that of insulin.
与胰岛素类似,亮氨酸在各种器官中刺激哺乳动物雷帕霉素靶蛋白 (mTOR)/p70 核糖体 S6 激酶 (p70(S6K)) 轴。胰岛素通过经典的磷脂酰肌醇 3-激酶 (PI3K)、磷酸肌醇依赖性蛋白激酶-1 (PDK1) 和蛋白激酶 B (PKB/Akt) 的关联进行。尽管已知亮氨酸的作用涉及不依赖于 PKB/Akt 的 PI3K 机制,但对其了解较少。在这项研究中,我们研究了 PDK1 是否也可以参与亮氨酸在心脏中引起的 mTOR/p70(S6K) 激活事件。在野生型心脏中,亮氨酸和胰岛素均增加 p70(S6K) 活性,而与胰岛素相反,亮氨酸不能激活 PKB/Akt。胰岛素和亮氨酸诱导的 p70(S6K) 活性变化与 mTOR 磷酸化位点 Thr(389)和 mTOR 上 Ser(2448)的磷酸化变化相关,这两个变化均与 mTOR 活性相关。亮氨酸还触发了 40 kDa 的富含脯氨酸的 Akt/PKB 底物 (PRAS40) 的磷酸化,这是一种新的关键 mTOR 调节剂。在 PDK1 敲除心脏中,亮氨酸与胰岛素相似,未能诱导 mTOR 和 p70(S6K) 的磷酸化,导致 p70(S6K) 激活缺失。在没有 PDK1 的情况下,亮氨酸的作用缺失与 PRAS40 磷酸化的缺失相关。此外,引入 PDK1 的 L155E 突变,该突变已知保留胰岛素诱导和 PKB/Akt 依赖性的 mTOR/p70(S6K) 磷酸化,抑制了所有亮氨酸作用,包括 mTOR、PRAS40 和 p70(S6K) 的磷酸化。我们得出结论,亮氨酸诱导的心脏 PRAS40/mTOR/p70(S6K) 途径的刺激需要 PDK1,这与胰岛素的方式不同。